Juho Jalkanen

Juho Jalkanen

Company: Faron Pharmaceuticals

Job title: Chief Operating Officer


Panel Discussion: How to Predict Your Immuno-Modulation & Immuno-Stimulatory Response? 3:25 pm

The potential of using IO, combinational or cell therapy to dial up another biologic to aid in the anti-tumour response. Could this be the next phase of development for immuno-oncology and what are the potential limitations of this approach? This panel will discuss: Methods of stimulating/dialling up a biologic Understanding of the differences between alternate…Read more

day: Day Two

Panel Discussion: Cutting Cancer Off At The Knees: Analysing the Preclinical Potential of Reprogramming/Repolarising Pro-Tumour Immune Cells 5:00 pm

The aggression of tumours is hugely linked with tumour survival mechanisms resulting in high-grade tumours. Assessing the implication of suppressor cells on the progression of tumours. Tumour-associated macrophages (TAMs) make up around 50% of the solid mass in a variety of human solid cancers (e.g., lung, breast and pancreatic) which are polarised into the M2…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.